With over twenty years of experience, this seasoned professional has joined the early-stage investment team in life sciences.
PARIS, September 10, 2024–(BUSINESS WIRE)–Sofinnova Partners (“Sofinnova”), a leading European venture capital firm focused on life sciences with offices in Paris, London and Milan, today announced the appointment of Karl Naegler as Partner. With this strategic hire, the firm is solidifying its expansion in Germany and consolidating its influence across Europe.
Karl Naegler will play a key role within Sofinnova Capital, the 35-year-old early-stage investment strategy. His expertise reinforces Sofinnova’s commitment to driving early-stage innovation in life sciences and enriches a well-established team of Partners.
Prior to joining Sofinnova, Karl Naegler was Managing Partner at Wellington Partners Life Sciences and Partner at Gimv, where he played a key role in the development of numerous startups throughout their journey from creation to sale. These include Seamless Therapeutics, recently created around a leading investor syndicate, Breath Therapeutics, a co-investment with Sofinnova and acquired by Zambon, Covagen acquired by Johnson & Johnson and Prosonix acquired by Circassia Pharmaceuticals.
“We have worked with Karl for twenty years and his track record speaks for itself,” said Graziano Seghezzi, Managing Partner at Sofinnova Partners. “His deep industry knowledge, impeccable reputation and strong relationship with Sofinnova make him an exceptional addition to the team. Karl’s arrival follows the recent promotion of Anta Gkelou from Principal to Partner and further strengthens our Senior Partner team.”
“Sofinnova is a leading global venture capital firm in life sciences in Europe,” said Karl Naegler. “It is a fantastic opportunity to be part of such a diverse investment platform, spanning such a wide range of sectors, stages and geographies, and led by such a talented team. I look forward to using my experience to develop and support the most innovative life sciences companies across Europe while strengthening our presence in Germany.”
Read more
Previously in his career, Karl Naegler worked at Ventech and Atlas Venture. He was also a researcher in neurochemistry at the CNRS in Strasbourg and obtained his doctorate in molecular neurobiology at the Max-Delbrück Center for Molecular Medicine in Berlin.
About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in the life sciences, with a focus on healthcare and sustainable development. Based in Paris, London and Milan, the team is composed of professionals from all regions of the world with scientific, business and medical backgrounds. As a committed investor, Sofinnova Partners is involved in creating companies across the entire life sciences value chain, from seed to late-stage development. The firm partners with ambitious entrepreneurs, as lead or lead investor, to develop innovations that have the potential to positively transform the future of all.
Founded in 1972, Sofinnova Partners is the most established venture capital firm in Europe. With 50 years of experience, it has supported more than 500 companies around the world that have become leaders in their markets. Sofinnova Partners currently manages more than €2.8 billion in assets. For more information: https://sofinnovapartners.com/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240909261792/fr/
Contacts
Bommy Lee
Head of Communications
Sofinnova Partners
[email protected]
+33 (0) 6 47 71 38 11
France
StrategiesImage
Anne Rein
[email protected]
+33 (0) 6 03 35 92 05
Related News :